Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 3.1%

Tiziana Life Sciences Ltd (NASDAQ:TLSAGet Rating)’s share price was up 3.1% on Friday . The stock traded as high as $0.66 and last traded at $0.65. Approximately 66,140 shares were traded during trading, a decline of 48% from the average daily volume of 128,258 shares. The stock had previously closed at $0.63.

Tiziana Life Sciences Price Performance

The stock’s 50 day moving average is $0.72 and its two-hundred day moving average is $0.75.

Hedge Funds Weigh In On Tiziana Life Sciences

A number of hedge funds have recently modified their holdings of TLSA. State Street Corp grew its position in Tiziana Life Sciences by 7.0% in the first quarter. State Street Corp now owns 318,788 shares of the company’s stock valued at $335,000 after acquiring an additional 20,799 shares during the period. Cantor Fitzgerald L. P. acquired a new stake in shares of Tiziana Life Sciences in the 3rd quarter valued at $36,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Tiziana Life Sciences in the 1st quarter worth about $91,000. 10.64% of the stock is owned by institutional investors and hedge funds.

About Tiziana Life Sciences

(Get Rating)

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

Read More

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.